Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.26+0.09 (+0.88%)
Close on Nov 11, 2026Market cap $170.12MP/E –Yield –
Sutro Biopharma cash
Cash and short-term investments held at the end of each period.
Sutro Biopharma's cash was $164.35M at Jun 30, 2026. For fiscal 2025 it was $141.43M, down 55.4% from the year before. The highest annual figure on record is $333.68M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.43M | -55.4% |
| FY2024 | Dec 31, 2024 | $316.90M | -5.0% |
| FY2023 | Dec 31, 2023 | $333.68M | +10.4% |
| FY2022 | Dec 31, 2022 | $302.34M | +88.1% |
| FY2021 | Dec 31, 2021 | $160.76M | -50.8% |
| FY2020 | Dec 31, 2020 | $326.49M | +177.0% |
| FY2019 | Dec 31, 2019 | $117.86M | -42.4% |
| FY2018 | Dec 31, 2018 | $204.49M | +828.7% |
| FY2017 | Dec 31, 2017 | $22.02M | +89.9% |
| FY2016 | Dec 31, 2016 | $11.59M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $164.35M | -19.9% |
| Q1 FY2026 | Mar 31, 2026 | $202.56M | -18.6% |
| Q4 FY2025 | Dec 31, 2025 | $141.43M | -55.4% |
| Q3 FY2025 | Sep 30, 2025 | $167.59M | -56.8% |
| Q2 FY2025 | Jun 30, 2025 | $205.13M | -45.4% |
| Q1 FY2025 | Mar 31, 2025 | $248.97M | -7.0% |
| Q4 FY2024 | Dec 31, 2024 | $316.90M | -5.0% |
| Q3 FY2024 | Sep 30, 2024 | $388.25M | +20.9% |
| Q2 FY2024 | Jun 30, 2024 | $375.57M | +4.8% |
| Q1 FY2024 | Mar 31, 2024 | $267.60M | +6.4% |
| Q4 FY2023 | Dec 31, 2023 | $333.68M | +10.4% |
| Q3 FY2023 | Sep 30, 2023 | $321.11M | +11.8% |
| Q2 FY2023 | Jun 30, 2023 | $358.29M | +87.0% |
| Q1 FY2023 | Mar 31, 2023 | $251.47M | +46.7% |
| Q4 FY2022 | Dec 31, 2022 | $302.34M | +88.1% |
| Q3 FY2022 | Sep 30, 2022 | $287.34M | +51.3% |
| Q2 FY2022 | Jun 30, 2022 | $191.63M | -14.2% |
| Q1 FY2022 | Mar 31, 2022 | $171.40M | -22.2% |
| Q4 FY2021 | Dec 31, 2021 | $160.76M | -50.8% |
| Q3 FY2021 | Sep 30, 2021 | $189.94M | -6.1% |
| Q2 FY2021 | Jun 30, 2021 | $223.42M | +11.0% |
| Q1 FY2021 | Mar 31, 2021 | $220.27M | +90.9% |
| Q4 FY2020 | Dec 31, 2020 | $326.49M | +177.0% |
| Q3 FY2020 | Sep 30, 2020 | $202.36M | +61.7% |
| Q2 FY2020 | Jun 30, 2020 | $201.36M | +31.5% |
| Q1 FY2020 | Mar 31, 2020 | $115.39M | -32.3% |
| Q4 FY2019 | Dec 31, 2019 | $117.86M | -42.4% |
| Q3 FY2019 | Sep 30, 2019 | $125.16M | +1.8% |
| Q2 FY2019 | Jun 30, 2019 | $153.16M | +502.5% |
| Q1 FY2019 | Mar 31, 2019 | $170.57M | +2471.9% |
| Q4 FY2018 | Dec 31, 2018 | $204.49M | +828.7% |
| Q3 FY2018 | Sep 30, 2018 | $122.95M | +383.9% |
| Q2 FY2018 | Jun 30, 2018 | $25.42M | +119.3% |
| Q1 FY2018 | Mar 31, 2018 | $6.63M | – |
| Q4 FY2017 | Dec 31, 2017 | $22.02M | – |
| Q3 FY2017 | Sep 30, 2017 | $25.41M | – |
| Q4 FY2016 | Dec 31, 2016 | $11.59M | – |
See a number that looks wrong?